| Literature DB >> 32189907 |
Suchitra Gosavi1, Harpreet Kaur2, Pramod Gandhi3.
Abstract
Brown tumor is unifocal or multifocal bone disease which represents terminal stage of hyperparathyroidism (HPT)-dependent bone pathology. It is recognized as a component of metabolic bone disease called osteitis fibrosa cystica generalisata or Von Recklinghausen disease of bone. HPT was first described by Von Recklinghausen in 1891. Brown tumor diagnosis nowadays is less frequently encountered because of early stage detection of HPT. This early detection is possible due to routine blood screening in asymptomatic adults or during evaluation of osteoporosis. Histologically, it may resemble any other giant cell lesion of the jaw that imposes diagnostic challenge and delay in treatment. We are introducing a case report of a 30-year-old female patient presented with multifocal osteolytic lesions in mandible with histopathology depictive of giant cell granuloma. Further biochemical investigations and X-ray skeletal changes raised the suspicion of primary HPT which was confirmed by parathyroid scintigraphy revealing parathyroid adenoma. The main purpose of this case report is to reinforce the role of oral examination in diagnosis of systemic diseases and to propose a diagnostic layout/algorithm when giant cells are present in biopsy specimen. Review of literature showing brown tumor of oral cavity associated with PHPT is discussed. Copyright:Entities:
Keywords: Brown tumor; giant cell lesion; parathyroid adenoma; parathyroid scintigraphy; primary hyperparathyroidism
Year: 2020 PMID: 32189907 PMCID: PMC7069142 DOI: 10.4103/jomfp.JOMFP_319_19
Source DB: PubMed Journal: J Oral Maxillofac Pathol ISSN: 0973-029X
Figure 1Traditional calcium, parathyroid hormone, and Vitamin D axis for the regulation of calcium homeostasis.[6] Under conditions of dietary calcium restriction, a decrement in serum calcium concentration induces release of parathyroid hormone from the parathyroid gland. Increased parathyroid hormone acts on the kidneys to stimulate renal 25(OH) D3-1α hydroxylase activity (1α-hydroxylase), which increases synthesis of the active form of Vitamin D (1α, 25-(OH) 2D3; calcitriol). Increased parathyroid hormone and 1α, 25-(OH) 2D3 target bone to induce a net resorption of calcium and phosphorus from mineralized tissue into circulation. Increased 1α, 25-(OH) 2D3 also targets the small intestine to stimulate active absorption of calcium and phosphorus through upregulation of proteins involved in calcium transport including calmodulin (calcium M), calbindin (calcium BP), transient receptor potential channel vanilloid 6 (TRPV6, also referred to as calcium transport protein 1) and calcium ATPase. The kidneys are ultimately required to restore serum calcium concentrations and maintain a calcium-to-phosphorus ratio. The increased 1α, 25-(OH) 2D3 stimulates renal calcium reabsorption through upregulation of calcium transport proteins and downregulation of phosphorus transport proteins (NaPi2a and NaPi2c). The net renal response results in a decreased excretion of calcium and an increased urinary excretion of P. Increased 1α, 25-(OH) 2D3 also serves as a feedback regulator to decrease 1α-hydroxylase activity. The net response to a decrement of serum calcium is a restoration of serum calcium with no effect on serum phosphorus
10 years review of literature of brown tumor of jaw associated with primary hyperparathyroidism till 2018
| Year and author | Age/sex (years) | Clinical presentation | Radiological features | Serum calcium | Serum phosphorus | Serum ALP | Serum PTH | Cause of PHPT | Treatment |
|---|---|---|---|---|---|---|---|---|---|
| Proimos E 2009 | 42/female | Facial pain and deformity | Round osteolytic lesion in anterior part of right maxillary sinus invading floor of orbit, anterior ethmoid sinus and nasal cavity | 13.2 mg/dl (N: 8.5-10.5 mg/dl) | 1.9 mg/dl (N: 2.50-4.50 mg/dl) | 227 U/L (N: Upto 115.00) | 920 pg/ml (N: 10-60.00 pg/ml) | Parathyroid adenoma | Referred to det of endocrinology |
| B. Chami | 43/female | Swelling in anterior palate approximately 4 cm × 3 cm | Palatal radiolucent destructive bone Lesion extending to the floor of nasal cavity and expanding the cortical plate | 148 mg/l (normal: 86-105) | 17 mg/l (normal: 25-50) | - | 8608 pg/ml; normal: 9-55 | Parathyroid adenoma | Surgical removal of mass |
| Soundarya, | 60/male | B/L maxillary swelling | Well-defined lytic lesion in maxilla, subperiosteal resorption of index finger | 7.7 mg/dL | 2.9 mg/dl | 747 U/L | 121 pg/ml | - | Complete resection of tumor |
| Elbuken G 2014 | 50/male | Sessile swelling on the anterior region of the maxilla (peripheral location | - | 10.6 mg/dl | 1.9 mg/dl | 430 U/L | 355 pg/mL | Parathyroid adenoma | Surgical removal of parathyroid mass |
| Shetty AD | 22/female | Diffuse hard, tender swelling over left side of face | Unilocular radiolucency wrt 34-36 region with associated root resorption | 12.5 mg/dl | 762 U/L | 452.5 pg/ml | Parathyroid hyperplasia | Surgical removal of parathyroid mass and curettage of bony lesions | |
| Abhishek Ranjan Pati | 34/male | Massive painful swelling in right maxilla | Osteolytic lesion in anterior part of right maxillary sinus invading floor of orbit, anterior ethmoid sinus and nasal cavity | 12 mg/dl | 6.7 mg/dl | 283 U/L | 314 pg/ml | Parathyroid adenoma | - |
| Rao | 55/female | Asymptomatic with intraoral diffuse swelling in left mandible | Well defined, multilocular radiolucency in the left body of the mandible with resorption of roots irt 34, 35 and 36 | 11.3 mg/dl | - | 134 U/L | 210 pg/ml | Parathyroid adenoma | Partial parathyroidectomy |
| B. Gogolewski 2017 | 27/female | Expansile mass in maxilla | Multifocal osteolytic lesions in maxilla and mandible | 1.8 mmol/L (N: 0.98-1.21 mmol/L | - | - | 653 pg/ml | Parathyroid adenoma | Right inferior parathyroidectomy |
| Kalapala L. 2016 | 42/female | Swelling over left side of face with I/O swelling in mandibular 34-37 region | Multilcular radiolucent lesion in posterior mandible, in skull parietal and osteolytic areas | 13.1 mg/dl | 10 mg/dl | - | 711 pg/ml | Parathyroid adenoma | - |
| Marcelo P 2017 | 35/male | Expansile lesion in left mandible | Unilocula radioluceny in left side of mandible | - | - | - | 502.8 pg/ml | - | Enucleation of the lesion, dental extraction of 36 element, curettage and synthesis of the region |
| Manoharan | 46/female | Expansile, hard mass in right and left nasolabial fold | Multiloculated osteolytic lesioninvolving both maxillae | 12.9 mg/dl | 2.1 mg/dl | - | 1900 pg/ml | Parathyroid adenoma | Surgical excision of lesion |
| Ojha SS 2018 | 62/female | Firm to hard swelling in anterior mandible | Expansile lytic lesion in midline of the mandible | 3.16 mmol/L | - | - | 516 pg/ml | Parathyroid adenoma | Surgical excision of lesion |
B/L: Bilateral, ALP: Alkaline phosphatase, PTH: Parathormone, PHPT: Primary hyperparathyroidism
Figure 2Extraoral and intraoral presentation of patient. Normal facial symmetry (a) and multifocal osteolytic lesions in anterior mandible, left posterior body, and right ramus of mandible (b)
Figure 4Three-dimensional re-construction of cone-beam computed tomography images and skeletal survey. Osteolytic lesions on right ramus, left postbody, and anterior region of mandible (yellow arrows a-c). Multiple discrete osteolytic lesions on spine, tibia, chest, and pelvis (d-g)
Figure 5Histopathology of lesion. Incisional biopsy showed multinucleated giant cells in the background of abundant hemorrhage (a and b). Excisional biopsy revealed similar picture (c and d)
Biochemistry report of patient
| Test | Patient’s findings | Normal range |
|---|---|---|
| Serum creatinine | 0.70 mg% | 0.60-1.40 mg% |
| Blood urea | 14.40 mg% | 20.00-40.00 mg% |
| Serum sodium | 138 mg/L | 135-145.00 mg/L |
| Serum potassium | 4.10 mg/L | 3.50-4.50 mg/L |
| GFR by MDRD formula | 105 | ≥60 mll/min/173 m2 |
| Serum calcium | 12.40 mg/dl | 9-11 mg/dl |
| Serum phosphorus | 1.40 mg/dl | 2.50-4.50 mg/dl |
| ALP | 2182 IU/L | Upto 115.00 |
| PTH assay | 706.04 pg/ml | 12-88.00 pg/ml |
PTH: Parathormone, GFR: Glomerular filtration rate, ALP: Alkaline phosphatase, MDRD: Modification of diet in renal disease study
Figure 6Parathyroid scintigraphy. The Tc-99M-tetrofosmin scan reveals abnormal large focus of intense tracer uptake in midline anterior neck, inferior to both lobes of the thyroid gland. Significant washout of tracer from thyroid gland is seen on delayed images with persistently seen focal tracer activity
Differential diagnosis of giant cell lesions
| Central giant cell lesions | Age | Sex | Site | Clinical features | Radiographic | Histopathology | Serum calcium | Serum phosphorus | Serum ALP |
|---|---|---|---|---|---|---|---|---|---|
| CGCG (nonneoplastic lesion) | <30 years | Female > male | Exclusively in jaws Anterior mandible crossing midline | Asymptomatic, seen during routine radiographic examination, nonaggressive form-painless expansion of affected bone, aggressive form-pain, cortical perforation and root resorption | Expansile, well demarcated, scalloped border, noncorticated multilocular, less commonly unilocular radiolucency | Loose fibrillar connective tissue with many interspersed proliferating fibroblasts, hemosiderin laden macrophages and extravasated RBCs, capillaries- snmall and inconspicuous, multinucleated giant cells are in focal aggregates or patches (zonation phenomenon) or diffusely scattered | N | N | N |
| Giant cell tumor (osteoclastoma)- benign but locally destructive neoplasm | 3rd-4th decade | Male > female | Rare in skull, preferential sites-sphenoid, ethmoid and temporal bones | Pain, swelling and pathological fracture | Radiolucent with poorly defined and irregular margins | Stromal cellularity is prominent, minimal collagen production. Mitotic figures may be found. Giant cells in larger, 40-60 nuclei than CGCG, more homogenous pattern of distribution. May contain inflammatory cells and areas of necrosis but relative absence of hemorrhage and hemosiderin pigment | N | N | N |
| PHPT (present case) | Female > male | Old age | Refer to text | Refer to text | Refer to text | Refer to text | ↑ | ↓ | N or osteolytic lesions |
| SHPT | Female > male | Old age | Same as PHPT | Same as PHPT | Same as PHPT | Same as PHPT | ↓ | ↑ | N or in osteolytic lesions |
| Cherubism - An AD disease SH3BP2 mutation on chromosome 4 | Female > male | 2-4 years, regresses after puberty | Mandible and maxilla | Characteristic renaissance cherub faces with rounded jaws, vertical displacement of orbital floor ‘eyes upturned to heaven appearance’, Submandibular and cervical lymphadenopathy-common | Bilateral symmetrical multilocular radiolucent lesions in the jaw with thick sclerotic borders. Unerupted teeth -“Floating tooth syndrome” | Numerous giant cells in a collagenous stroma, containing abundant fibroblasts. Perivascular eosinophilic cuffing is specific for the lesion | N | N | N (in active growth period there may be physiological increase in ALP) |
| Noonan like multiple gaint cell lesion syndrome-AD | - | Congenital anomaly | - | Short stature, craniofacial dysmorphisms and congenital heart defects | Multilocular radiolucency | Numerous giant cells in a collagenous stroma, containing abundant fibroblasts. Perivascular eosinophilic cuffing is specific for the lesion | N | N | N (in active growth period there may be physiological increase in ALP) |
| Aneurysmal bone cyst | Male=female | <20 years | Nearly every part of skeleton, long bones, vertebral column- common Mandible > maxilla | Painful firm swelling Two clinicopathologic forms: Primary lesion/a secondary lesion (arising in other neoplastic/nonneoplastic osseous conditions) | Multilocular radiolucency with honeycomb or soap bubble appearance, eccentrically ballooned | Cavernous or sinusoidal blood filled spaces without endothelial lining. Giant cells (patchy distribution similar to CGCG) along with varying amounts of hemosiderin pigment are present | - | - | - |
↑: Increase downward arrow decrease. ALP: Alkaline phosphatase, CGCG: Central Giant cell granuloma, PHPT: Primary hyperparathyroidism, SHPT: Secondary hyperparathyroidism
Figure 7Algorithm for diagnosis and treatment of primary hyperparathyroidism and exclusion of other giant cell lesions